Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast CancerOlivia Pagani, Prudence A. Francis, Silvana Martino et al.|New England Journal of Medicine|2014Cited by 751
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 studyJoyce F. Liu, Ursula A. Matulonis, William T. Barry et al.|The Lancet Oncology|2014Cited by 586
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Barbara Walley, Weixiu Luo et al.|The Lancet Oncology|2015Cited by 179
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Joanna Vermeij, Weixiu Luo et al.|The Lancet Oncology|2017Cited by 122
A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.Joyce F. Liu, Ursula A. Matulonis, William T. Barry et al.|Journal of Clinical Oncology|2014Cited by 22